If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Abasaglar Summary of Product Characteristics (SmPC)
Abasaglar® (insulin glargine): Transitioning from basal insulin
If transitioning from another basal insulin to Abasaglar, the recommended initial Abasaglar dose is based on the insulin therapy that is being discontinued.
transitioning patients from another basal insulin to Abasaglar
therapy, the recommended initial dose of Abasaglar is based on the
insulin therapy that is being discontinued (Table
in the Abasaglar dose when transitioning from certain insulins will
lower the likelihood of hypoglycemia.1,2
1. Transitioning From Another Basal Insulin to Abasaglar Therapy1,2
the recommended initial dose of Abasaglar …
the same as the Lantus dose.
units of Lantus transitions to 50 units of Abasaglar
80% of the Toujeo dose.
units of Toujeo transitions to 40 units of Abasaglar
70%-80% of the total daily NPH insulin dosage.
units of NPH insulin every morning and 25 units of NPH insulin
every evening, for a daily total of 50 units of NPH insulin,
transitions to 35 units (70% of the NPH insulin total daily dose)
or 40 units (80% of the NPH insulin total daily dose) of Abasaglar
intermediate- or long-acting insulin other than Lantus
differ from the prior basal insulin dose and other concomitant
antihyperglycemic medications may need to be adjusted.